10 Press Releases You Need to See This Week
NEW YORK, May 30, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.
The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.
JetBlue and United Announce Blue Sky: Unique Consumer Collaboration That Links Loyalty ProgramsMileagePlus customers can earn and use miles on JetBlue including hundreds of flights in and out of New York City and Boston while TrueBlue members can earn and use points on United flights including to popular international destinations like Cape Town and Tahiti.
The Hefty® Brand Celebrates 60 Years of Strength with Limited-Edition Birthday Cake-Scented Trash BagsTo put a festive spin on household cleanup, the brand infused the familiar 20-count 13-gallon tall kitchen trash bags with the nostalgic scent of vanilla frosting and rainbow sprinkles – bringing a bit of birthday magic to trash day.
Bain & Company forms global partnership with Palantir to deliver high impact, end-to-end AI transformations for clientsThe partnership enables clients worldwide to accelerate AI-driven productivity gains with enhanced speed and efficiency through Palantir's cutting-edge enterprise AI platforms, yielding tangible impact in weeks.
Pizza Hut Debuts First-Ever BOOK IT!® AppThe new app officially launched this month and is designed to help parents keep their children engaged in reading all summer long. This new digital tool empowers families to track progress of their child's reading, set goals and earn pizza rewards all while preventing the "Summer Slide."
Spirit Airlines Rolls Out Refreshed Inflight Menu with New Offerings and 'More Fly' LookThe refreshed menu introduces 12 new items and combos, including sweet and savory snacks and alcoholic and non-alcoholic beverages. "Plus, Guests who choose a premium experience with Go Big can enjoy complimentary options to sip and snack on," said Dana Shapir Alviene, Senior Vice President of Inflight and Airport Experience at Spirit Airlines.
Sony Electronics Introduces the FX2 Compact Camera, Expanding Cinema Line's Versatility for Creatives"The hybrid cinema camera was created based on user feedback and is engineered with unique features to support filmmaking, a new eyepiece, and enhancements for versatile production needs," says Theresa Alesso, President, Imaging Products and Solutions Americas, Sony Electronics Inc.
PepsiCo® Announces Worldwide Official Partnership with Formula 1®As an Official Partner of Formula 1, PepsiCo has secured comprehensive rights, including: TV-visible trackside advertising; Fan Zone activation opportunities at 21 races; tickets and hospitality experiences; exclusive marketing rights for featured brands; and exclusive track pouring and product supply rights, across global race venues.
US Consumer Confidence Partially Rebounds in MayMay's rebound in confidence was broad-based across all age groups and all income groups. It was also shared across all political affiliations, with the strongest improvements among Republicans. However, on a six-month moving average basis, confidence in all age and income groups was still down due to previous monthly declines.
Rental-hunting season hits fever pitch as June begins, Zillow data shows"Knowing when demand spikes can help renters plan ahead, act quickly and use smart tools to find a place that checks all their boxes without blowing their budget. You'll still have options later if you miss the rush, but you might miss out on freebies available now," said Emily McDonald, Zillow rental trends expert.
John Deere Acquires Sentera to Integrate Aerial Field ScoutingThis acquisition will advance the capabilities of John Deere's existing technology offerings, providing farmers and ag service providers with a more comprehensive set of tools to generate and use data to make decisions that improve farm profitability, efficiency, and sustainability.
Read more of the latest releases from PR Newswire.
Do you have a press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.
Helping Journalists Stay Up to Date on Industry News
These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.
Once they're signed up, reporters, bloggers, and freelancers have access to the following free features:
Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.
Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story.
Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.
Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.
About PR Newswire
PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.
For questions, contact the team at media.relations@cision.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/10-press-releases-you-need-to-see-this-week-302468964.html
SOURCE PR Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Vlahovic and Goncalo Ramos' future intertwined as United wait
Manchester United may lose two of their potential striking targets to the same team. Striker search After missing out on Liam Delap, Viktor Gyokeres and Hugo Ekitike to Premier League rivals, United are still searching for number nine solutions. The news broke yesterday that United had narrowed their search down to Aston Villa's Ollie Watkins and Red Bull Leipzig's Benjamin Sesko. Nonetheless, should United also miss out on these options, they have been linked to loan options that could come at the end of August. Loan opportunities Juventus' relationship with Dusan Vlahovic is at an all-time low and the club is desperate to see the player leave the club this summer. Moreover, United have been linked to the Serbian and have also been credited with interest in Paris Saint-Germain's Portuguese attacker, Goncalo Ramos. AC Milan lurking United could swoop for either player but this is under threat by the summer activity of Italian giants AC Milan. The Rossoneri's interest in Vlahovic has already been reported on. Italian outlet Calciomercato assert that 'AC Milan is trying to intensify contacts to find the right formula for signing the Juventus number nine. This signing will only happen if the player reduces his net salary to €6-7 million.' The Juventus striker is said to be the club's 'main priority' but the club does have a back-up plan, involving another United target. It is reported that 'AC Milan, however, is also considering other options and their plan B is Goncalo Ramos, the Portuguese striker owned by PSG, who is seeking more playing time and who is looking at his transfer options.' PSG have no intention of selling Ramos, who they paid €65 million just two years ago. Nonetheless, they could be open to a loan move, something that Milan would favour due to their restricted financial situation. Featured image Michael Reaves via Getty Images online polls Follow us on Bluesky: @
Business Wire
7 minutes ago
- Business Wire
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory and underscoring its commitment to delivering sustainable value through innovation. Most notably, both Phase 3 studies of oveporexton successfully met all primary and secondary endpoints, demonstrating statistically significant improvements across doses. These results reinforce the potential of oveporexton to transform the standard of care in narcolepsy type 1. In addition, Takeda received U.S. FDA approval for GAMMAGARD ® LIQUID ERC and European Commission (EC) approval for ADCETRIS ® in new indications and presented promising clinical data for rusfertide at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session. These developments underscore the strength of Takeda's late-stage pipeline and its potential to drive future growth. Takeda chief financial officer, Milano Furuta, commented: 'The impact of VYVANSE generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May. 'Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth.' Core (Non-IFRS) (Billion yen, except percentages and per share amounts) FY2025 Q1 FY2024 Q1 vs. PRIOR YEAR (Actual % change) vs. PRIOR YEAR (CER % change) Revenue 1,106.7 1,208.0 -8.4% -3.7% Operating Profit 321.8 382.3 -15.8 % -11.9% Margin 29.1% 31.6% -2.6 pp ― Net Profit 237.0 276.8 -14.4% -10.3% EPS (Yen) 151 176 -14.1% -10.0% Expand FY2025 Outlook (unchanged from May 2025) (Billion yen, except percentages and per share amounts) Revenue 4,530.0 --- Core Revenue (Non-IFRS) 4,530.0 Broadly flat Operating Profit 475.0 --- Core Operating Profit (Non-IFRS) 1,140.0 Broadly flat Net Profit 228.0 --- EPS (Yen) 145 --- Core EPS (Yen) (Non-IFRS) 485 Broadly flat Adjusted Free Cash Flow (Non-IFRS) 750.0-850.0 --- Annual Dividend per Share (Yen) 200 --- Expand Additional Information About Takeda's FY2025 Q1 Results For more details about Takeda's FY2025 Q1 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda's FY2025 Q1 investor presentation (available at About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Important Notice For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Financial information and Non-IFRS Measures Takeda's financial statements are prepared in accordance with International Financial Reporting Standards ('IFRS'). This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ('CER') change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda's non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as 'reported' measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2025 Q1 investor presentation (available at Peak Sales and PTRS Estimates References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda's assessments of various possible future commercial scenarios that may or may not occur. References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda's Portfolio Review Committee for use in internal planning. Medical information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Please refer to slide 6 of Takeda's FY2025 Q1 investor presentation (available at for the definition of Growth & Launch Products.
Business Upturn
an hour ago
- Business Upturn
Hatton National Bank partners with Nucleus Software to upgrade transaction banking with FinnAxia®
By News Desk Published on July 30, 2025, 09:44 IST Nucleus Software Exports Ltd. has announced a strategic partnership with Hatton National Bank PLC (HNB), one of Sri Lanka's premier private banks, to enhance its transaction banking capabilities through the deployment of FinnAxia®, Nucleus's advanced transaction banking suite. The collaboration is aimed at helping HNB accelerate digital transformation, particularly in the areas of payments, cash management, and corporate banking services. The rollout of FinnAxia® is a key step in HNB's ambition to strengthen its leadership in the SME and corporate banking segments, both domestically and internationally. 'We are reimagining our transaction banking strategy to not only retain our leadership position in the payments and cash management space but to significantly expand our presence in the SME and corporate banking segments,' said Damith Pallewatte, Managing Director & CEO, HNB. 'FinnAxia® gives us the technology edge to offer a comprehensive, digital-first experience.' Since going live, HNB has reported a 10X increase in customer onboarding and a 6X jump in transaction volumes, showcasing early success of the implementation. The platform enables real-time dashboards, automated reconciliation, and enhanced visibility, which is critical for treasuries to make data-driven decisions. Vishnu R. Dusad, Managing Director and Co-Founder of Nucleus Software, stated: 'With FinnAxia®, we are not just delivering technology, but building a competitive advantage. Our partnership with HNB reflects a shared ambition to redefine digital transaction banking in Sri Lanka.' Ahmedabad Plane Crash News desk at
